Date: 6th-10th October, 2024
Location: Lima, Peru
At HIVR4P 2024, the 5th HIV Research for Prevention Conference, HPTN researchers presented 15 oral and poster presentations covering HPTN 083-01, HPTN 084, HVTN 127/ HPTN 087, HVTN 130/HPTN 089, HPTN 091, HVTN 136/HPTN 092, HVTN 805/HPTN 093/A5393, HVTN 804/HPTN 095, HVTN 140/HPTN 101, A5416/HVTN 806/HPTN 108, and HPTN 111. This conference fosters interdisciplinary knowledge exchange on HIV vaccines, microbicides, PrEP, treatment as prevention, and biomedical interventions, as well as their social and behavioral implications.
Presented Research:
Presentations
Analytical treatment interruption (ATI) in Peru among MSM, trans & gender non-conforming (GNC) individuals with early ART initiation +/- VRC01 proximate to HIV acquisition: Stakeholder engagement & early clinical data – Jorge Gallardo-Cartagena
Assessment of infusion-related reactions after intravenous administration of HIV monoclonal antibodies PGT121.414.LS, PGDM1400.LS or VRC07-523LS (alone or in combination with PGT121, PGDM1400, 10-1074, PGT121.414.LS, PGDM1400.LS), in five phase 1 studies – Silvia P Goulart
Evaluation of potential pharmacologic interactions between CAB-LA or TDF/ FTC and hormonal contraceptive agents: a tertiary analysis of HPTN 084 – Mark Marzinke
Posters
- Exploring relationship dynamics: the impact of disclosure and partner influence on oral and injectable PrEP adherence among users and their intimate partners (HPTN 084 qualitative findings) – Makhosazane Nomhle Ndimande-Khoza
HVTN 805/HPTN 093/A5393 Analytical Treatment Interruption (ATI) among African women with early ART initiation +/- VRC01 received within 8 weeks of HIV acquisition: safety, viral rebound and virologic control – Shelly Karuna
Engagement and training of barbers to deliver an HIV prevention intervention to their clients (HPTN 111) – Joel Maena
Acceptability of intravenous (IV) and subcutaneous (SC) infusion administration of monoclonal antibody (mAb) combinations: VRC07-523LS with PGT121, PGDM1400, PGT121.414.LS and PGDM1400LS in phase 1 anti-HIV mAb trials – Maija Alanya Anderson
Facilitators, barriers and robust informed consent for HVTN805/HPTN093/A5393 analytical treatment interruption (ATI) participation: insights from ATI participants and decliners screened from the antibody mediated prevention (AMP) study in Southern Africa – Shelly Karuna
Recommendations made during Community consultations for analytical treatment interruption (ATI) HIV research studies in Southern Africa – Matshidiso Adelaide Malefo
Can intention studies predict PrEP uptake? Systematic review and meta-analysis of PrEP studies on intention and uptake across populations in sub-Saharan Africa – Jose Luis Paredes